Compare EPAM Systems Inc (EPAM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Sanofi SA — how do they compare? EPAM Systems Inc trades at $113.53 (market cap $5.87B), while Sanofi SA trades at $40.11 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16.2× EPAM Systems Inc's market cap, and Sanofi SA pays a 6.01% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Sanofi SA for 94 Days on average.
| EPAM | SNY | |
|---|---|---|
Market Cap | $5.87B | $95.18B |
Volume | 847,420 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $221.40 | $52.34 |
52-Week Low | $76.04 | $39.51 |
Typical Hold Time | 37 Days | 94 Days |
Enterprise Value | $5.24B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.54, up 4.82% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $119 suggest upside potential. The company reported $5.46B in 2025 revenue, with a net income margin of 7.15%, while maintaining solid cash flow from operations of $654.93M.
The outlook is positive, driven by AI-native revenue growth exceeding 11% and activist shareholder pressure for buybacks. Risks include slower North American growth and competitive pressures in digital transformation services. The stock's current valuation at a P/E of 15.45 appears reasonable relative to earnings growth prospects.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
